- Price
- $56.99
- Day
- +3.36%
- Mkt Cap
- $22.61B
- 52W Range
- $22.28 – $85.60
- Volume
- 3.93M
- Beta
- 0.94
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine.
Read full article
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), building on Moderna's prior filovirus research CAMBRIDGE, MA / ACCESS Newswire / August 4, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company's investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus, or BDBV, disease. The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic.
Read full article
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
Read full article
Cloud growth boosts Amazon's results, Apple has supply chain struggles, and more
Read full article
Moderna Inc (MRNA) released its 8-K filing on July 31, 2026, reporting its financial results for the second quarter of the fiscal year. For the quarter, Moderna
Read full article
Moderna NASDAQ: MRNA reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases.
Read full article
Moderna missed Wall Street estimates for second-quarter revenue on Friday, hit by weaker-than-expected sales of its COVID-19 shot, ahead of an upcoming regulatory decision for its experimental flu vaccine.
Read full article
Stock futures pointed to a higher open as Big tech earnings continue to roll out and lift the beaten down market
Read full article
Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.
Read full article
The drugmaker's top line continues to be heavily influenced by Covid vaccine sales.
Read full article
Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate Announces that mRNA-1403, Moderna's norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis and the Company is preparing to enroll an additional cohort CAMBRIDGE, MA / ACCESS Newswire / July 31, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2026. "The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook," said Stéphane Bancel, Chief Executive Officer of Moderna.
Read full article
Moderna (MRNA) came out with a quarterly loss of $1.97 per share in line with the Zacks Consensus Estimate. This compares to a loss of $2.13 per share a year ago.
Read full article